Effect of recombinant bovine basic fibroblast growth factor gel on repair of rosacea skin lesions: A randomized, single‑blind and vehicle‑controlled study

Luo,Yang; Luan,Xiu‑Li; Sun,Yu‑Jiao; Zhang,Li; Zhang,Jian‑Hong

doi:10.3892/etm.2019.7258

Effect of recombinant bovine basic fibroblast growth factor gel on repair of rosacea skin lesions: A randomized, single‑blind and vehicle‑controlled study

Authors:
- Yang Luo
- Xiu‑Li Luan
- Yu‑Jiao Sun
- Li Zhang
- Jian‑Hong Zhang
View Affiliations

Affiliations: Department of Dermatology, Lanzhou General Hospital, Lanzhou, Gansu 730050, P.R. China
Published online on: February 12, 2019 https://doi.org/10.3892/etm.2019.7258
Pages: 2725-2733
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to assess the effect of topical use of recombinant bovine basic fibroblast growth factor (rbFGF) gel on the repair of facial skin lesions in patients with rosacea. In the present single‑blind study, a total of 1,287 patients with Demodex mite‑induced rosacea who received treatment with ornidazole tablets were randomized to rbFGF gel treatment group (n=651) or control group (n=636) without revealing the group identity. Patients in the treatment group were treated with topical application of rbFGF gel over the skin lesions (0.2 g/cm2) for up to 8 weeks, whereas patients in the control group received gel vehicle treatment unless ulceration occurred. Skin lesions of all patients were scored prior to and following treatment with rbFGF gel and subjected to histological analysis. All patients were followed up for 6 months. Significant improvement in the total effective rates for erythema, papules, desquamation and dryness were observed in the rbFGF treatment group. At the end of the 2, 4 and 6 months of follow‑up, the total effective rates for patients in the treatment group were significantly higher than those in the control group (81.67 vs. 28.84%; 85.11 vs. 40.81%, and 96.56 vs. 55.82%, respectively). Following treatment for 6 months, none of the patients in the rbFGF group exhibited ulceration or scar formation. In the control group, 61% of patients experienced exacerbation of skin lesions, of which, 12% exhibited ulceration and were treated with rbFGF gel to prevent scar formation. Histological analysis revealed gradual reduction in epidermal hyperplasia and resolution of dermal edema in skin lesions treated with rbFGF gel. In conclusion, rbFGF gel may improve the repair of facial rosacea skin lesions in patients treated with anti‑Demodex.

View Figures

View References

1	Weinkle AP, Doktor V and Emer J: Update on the management of rosacea. Clin Cosmet Investig Dermatol. 8:159–177. 2015.PubMed/NCBI
2	Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J and Thiboutot D: Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 78:148–155. 2018. View Article : Google Scholar : PubMed/NCBI
3	Egeberg A, Hansen PR, Gislason GH and Thyssen JP: Patients with Rosacea have increased risk of depression and anxiety disorders: A Danish Nationwide Cohort Study. Dermatology. 232:208–213. 2016. View Article : Google Scholar : PubMed/NCBI
4	Libon F, El Hayderi L, Nikkels-Tassoudji N, Dezfoulian B and Nikkels AF: Rosacea. Rev Med Liege. 70:179–185. 2015.(In French). PubMed/NCBI
5	Gonzalez-Hinojosa D, Jaime-Villalonga A, Aguilar-Montes G and Lammoglia-Ordiales L: Demodex and rosacea: Is there a relationship? Indian J Ophthalmol. 66:36–38. 2018. View Article : Google Scholar : PubMed/NCBI
6	Cohen PR: Follicular contact dermatitis revisited: A review emphasizing neomycin-associated follicular contact dermatitis. World J Clin Cases. 2:815–821. 2014. View Article : Google Scholar : PubMed/NCBI
7	Chang YS and Huang YC: Role of Demodex mite infestation in rosacea: A systematic review and meta-analysis. J Am Acad Dermatol. 77:441–447.e6. 2017. View Article : Google Scholar : PubMed/NCBI
8	Luo Y, Sun YJ, Zhang L and Luan XL: Treatment of mites folliculitis with an ornidazole-based sequential therapy: A randomized trial. Medicine (Baltimore). 95:e41732016. View Article : Google Scholar : PubMed/NCBI
9	Zarei F and Soleimaninejad M: Role of growth factors and biomaterials in wound healing. Artif Cells Nanomed Biotechnol. 1–6. 2018.PubMed/NCBI
10	Jinfeng L, Yunliang W, Xinshan L, Shanshan W, Chunyang X, Peng X, Xiaopeng Y, Zhixiu X, Honglei Y, Xia C, et al: The effect of MSCs derived from the human umbilical cord transduced by fibroblast growth factor-20 on Parkinson's disease. Stem Cells Int. 2016:50167682016. View Article : Google Scholar : PubMed/NCBI
11	Meduri A, Scorolli L, Scalinci SZ, Grenga PL, Lupo S, Rechichi M and Meduri E: Effect of the combination of basic fibroblast growth factor and cysteine on corneal epithelial healing after photorefractive keratectomy in patients affected by myopia. Indian J Ophthalmol. 62:424–428. 2014. View Article : Google Scholar : PubMed/NCBI
12	Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R and Powell F: Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 46:584–587. 2002. View Article : Google Scholar : PubMed/NCBI
13	Rong L, Ding T and Zhou Y: Different methods in the treatment of rosacea and effect observation of staging. Sichuan Medical J. 35:444–445. 2014.
14	Tan JK: Evaluation of clinical severity by acne grading and lesion counting. Springer Berlin. (Heidelberg). 325–330. 2014.
15	Luo Y, Zhang LI, Sun YJ, Du H and Yang GL: Syringotropic mycosis fungoides responding well to VELP chemotherapy: A case report. Exp Ther Med. 11:2254–2258. 2016. View Article : Google Scholar : PubMed/NCBI
16	Alebachew T, Yismaw G, Derabe A and Sisay Z: Staphylococcus aureusburn wound infection among patients attending yekatit 12 hospital burn unit, addis ababa, ethiopia. Ethiop J Health Sci. 22:2092012.PubMed/NCBI
17	Del Rosso JQ, Tanghetti EA, Baldwin HE, Rodriguez DA and Ferrusi IL: The burden of illness of erythematotelangiectatic rosacea and papulopustular rosacea: Findings from a web-based survey. J Clin Aesthet Dermatol. 10:17–31. 2017.PubMed/NCBI
18	Rainer BM, Kang S and Chien AL: Rosacea: Epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 9:e13615742017. View Article : Google Scholar : PubMed/NCBI
19	Mikkelsen CS, Holmgren HR, Kjellman P, Heidenheim M, Kappinnen A, Bjerring P and Huldt-Nystrøm T: Rosacea: A clinical review. Dermatol Reports. 8:63872016. View Article : Google Scholar : PubMed/NCBI
20	Tüzün Y, Wolf R, Kutlubay Z, Karakuş O and Engin B: Rosacea and rhinophyma. Clin Dermatol. 32:35–46. 2014. View Article : Google Scholar : PubMed/NCBI
21	Oge LK, Muncie HL and Phillips-Savoy AR: Rosacea: Diagnosis and treatment. Am Fam Physician. 92:187–196. 2015.PubMed/NCBI
22	van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM and Charland L: Interventions for rosacea. Cochrane Database Syst Rev. CD003262. 2015. View Article : Google Scholar
23	Ebbelaar CCF, Venema AW and Van Dijk MR: Topical ivermectin in the treatment of papulopustular rosacea: A systematic review of evidence and clinical guideline recommendations. Dermatol Ther (Heidelb). 8:379–387. 2018. View Article : Google Scholar : PubMed/NCBI
24	Piwnica D, Pathak A, Schäfer G and Docherty JR: In vitro safety pharmacology profiling of topical α-adrenergic agonist treatments for erythema of rosacea. Drugs R D. 18:87–90. 2018. View Article : Google Scholar : PubMed/NCBI
25	Piwnica D, M Pathak A, Schafer G and Docherty JR: In vitro safety pharmacology profiling of topical alpha-adrenergic agonist treatments for erythema in wounded skin. J Cell Sci. 125:5690–5701. 2012.PubMed/NCBI
26	Zbinden A, Browne S, Altiok EI, Svedlund FL, Jackson WM and Healy KE: Multivalent conjugates of basic fibroblast growth factor enhance in vitro proliferation and migration of endothelial cells. Biomater Sci. 6:1076–1083. 2018. View Article : Google Scholar : PubMed/NCBI
27	Chen G, Ren J, Deng Y, Wu X, Huang J, Wang G, Zhao Y and Li J: An injectable, wound-adapting, self-healing hydrogel for fibroblast growth factor 2 delivery system in tissue repair applications. J Biomed Nanotechnol. 13:1660–1672. 2017. View Article : Google Scholar : PubMed/NCBI
28	Qu Y, Cao C, Wu Q, Huang A, Song Y, Li H, Zuo Y, Chu C, Li J and Man Y: The dual delivery of KGF and bFGF by collagen membrane to promote skin wound healing. J Tissue Eng Regen Med. 12:1508–1518. 2018. View Article : Google Scholar : PubMed/NCBI
29	Marcelo KL, Goldie LC and Hirschi KK: Regulation of endothelial cell differentiation and specification. Circ Res. 112:1272–1287. 2013. View Article : Google Scholar : PubMed/NCBI
30	Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH and Jacovella J;: Ivermectin Phase III study group: Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: A randomized, investigator-blinded trial. Br J Dermatol. 172:1103–1110. 2015. View Article : Google Scholar : PubMed/NCBI
31	DuBois J, Dover JS, Jones TM, Weiss RA, Berk DR and Ahluwalia G: Phase 2 randomized, dose-ranging study of oxymetazoline cream for treatment of persistent facial erythema associated with rosacea. J Drugs Dermatol. 17:308–316. 2018.PubMed/NCBI
32	Gold LS, Papp K, Lynde C, Lain E, Gooderham M, Johnson S and Kerrouche N: Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: A randomized, vehicle-controlled study. J Drugs Dermatol. 16:909–916. 2017.PubMed/NCBI
33	Friedman LM, Furberg CD, DeMets D, Reboussin DM and Granger CB: Fundamentals of clinical trials. Springer. 2015.